Suggested remit: To appraise the clinical and cost effectiveness of luspatercept within its marketing authorisation for treating anaemia in non-transfusion dependent beta-thalassaemia.
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
- ID number:
- 3870
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 February 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia. Please note that following on from information received from the company the timelines for this appraisal are to be confirmed. NICE will continue to monitor the situation and will update interested parties as and when the situation changes. |
| 10 November 2021 - 08 December 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual